EGFR and head and neck squamous cell carcinoma: The three drugs that were initially selected on the basis of their reactivity toward the EGFR-RAF-MEK-ERK pathway, i.e., cetuximab, erlotinib and sorafenib, displayed neighbouring activity in terms of effect on tumour cell proliferation in HNSCC.